Upgrade to SI Premium - Free Trial

Amarin Corp. (AMRN) Tops Q3 EPS by 4c, Revenues Beat

November 5, 2019 5:50 AM

Amarin Corp. (NASDAQ: AMRN) reported Q3 EPS of ($0.01), $0.04 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $112.4 million versus the consensus estimate of $110.04 million.

“Our aim is to help as many patients as possible with Vascepa. Accordingly, we are pleased to witness the growth in Vascepa usage as reported in the third quarter. These recent results are laying the foundation for our future growth as we seek to make Vascepa a new standard of care for use in appropriate at-risk patient populations based on REDUCE-IT,” stated John F. Thero, president and chief executive officer. “We are appreciative of the many patients and health care professionals who have reached out to us expressing support for approval of Vascepa for the expanded indication being sought. We are working with leading physicians to ensure that the results of the landmark REDUCE-IT study are well understood by regulatory authorities and their advisors. We recognize that much work remains following the anticipated approval of Vascepa. We remain guided by science and highly motivated by the unmet medical need that we believe Vascepa can address.”

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.

Categories

Corporate News Earnings Management Comments

Next Articles